Relx (LON:REL) Lowered to Underperform at BNP Paribas

BNP Paribas lowered shares of Relx (LON:REL) to an underperform rating in a research report released on Tuesday morning, Stock Target Advisor reports. The brokerage currently has GBX 1,650 ($20.31) price objective on the stock, down from their previous price objective of GBX 1,900 ($23.38).

Other analysts have also issued reports about the stock. UBS Group reaffirmed a neutral rating and issued a GBX 1,790 ($22.03) price target (down from GBX 1,790 ($22.03)) on shares of Relx in a research note on Thursday, May 28th. Goldman Sachs Group reissued a buy rating and set a GBX 2,189 ($26.94) target price on shares of Relx in a research note on Wednesday, April 8th. Berenberg Bank reissued a hold rating and set a GBX 2,080 ($25.60) target price (down from GBX 2,100 ($25.84)) on shares of Relx in a research note on Friday, June 26th. JPMorgan Chase & Co. reissued an overweight rating and set a GBX 2,000 ($24.61) target price on shares of Relx in a research note on Friday, June 26th. Finally, Barclays upped their price target on shares of Relx from GBX 1,860 ($22.89) to GBX 1,910 ($23.50) and gave the company an overweight rating in a research report on Thursday, April 9th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating to the company. The stock has an average rating of Hold and an average price target of GBX 1,947.64 ($23.97).

Shares of LON:REL opened at GBX 1,870 ($23.01) on Tuesday. The company has a quick ratio of 0.33, a current ratio of 0.41 and a debt-to-equity ratio of 293.11. Relx has a fifty-two week low of GBX 1,382.86 ($17.02) and a fifty-two week high of GBX 2,109 ($25.95). The firm has a 50-day simple moving average of GBX 1,873.86 and a 200 day simple moving average of GBX 1,866.46. The company has a market cap of $37.07 billion and a PE ratio of 24.75.

Relx Company Profile

RELX PLC provides information based-analytics and decision tools for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals that enables progress in science, advance healthcare, and performance improvement.

Read More: Compound Interest

Analyst Recommendations for Relx (LON:REL)

Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.